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Abstract
Helicobacter pylori (HP) is a bacterium that colonizes the human stomach and can establish a long-term infection of the
gastric mucosa. Persistent Hp infection often induces gastritis and is associated with the development of peptic ulcer
disease, atrophic gastritis, and gastric adenocarcinoma. Virulent HP isolates harbor the cag (cytotoxin-associated genes)
pathogenicity island (cagPAI), a 40 kb stretch of DNA that encodes components of a type IV secretion system (T4SS). This
T4SS forms a pilus for the injection of virulence factors into host target cells, such as the CagA oncoprotein. We analyzed the
genetic variability in cagA and other selected genes of the HP cagPAI (cagC, cagE, cagL, cagT, cagV and cag Gamma) using
DNA extracted from frozen gastric biopsies or from clinical isolates. Study subjects were 95 cagA+ patients that were
histologically diagnosed with chronic gastritis or gastric cancer in Venezuela and Mexico, areas with high prevalence of Hp
infection. Sequencing reactions were carried out by both Sanger and next-generation pyrosequencing (454 Roche)
methods. We found a total of 381 variants with unambiguous calls observed in at least 10% of the originally tested samples
and reference strains. We compared the frequencies of these genetic variants between gastric cancer and chronic gastritis
cases. Twenty-six SNPs (11 non-synonymous and 14 synonymous) showed statistically significant differences (P,0.05), and
two SNPs, in position 1039 and 1041 of cagE, showed a highly significant association with cancer (p-value=2.07610
26), and
the variant codon was located in the VirB3 homology domain of Agrobacterium. The results of this study may provide
preliminary information to target antibiotic treatment to high-risk individuals, if effects of these variants are confirmed in
further investigations.
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Introduction
Helicobacter pylori (HP) is one of the most common chronic
bacterial infection in humans. It has been estimated that more
than half of the adult population in the world is infected with this
organism [1]. Among these, approximately 10–15% of the infected
individuals are estimated to experience clinically adverse sequelae,
including peptic ulcers, gastric adenocarcinoma and gastric
mucosa-associated lymphoid tissue lymphoma (MALT) [2]. To
date, despite extensive effort worldwide, what determines these
variable clinical outcomes has not been fully elucidated, but
believed to be combinations of environmental (e.g., smoking and
diet) [3], host genetics and HP virulence factors [3,4,5]. Work by
us [6] and others support that bacterial factors are likely to play
the most decisive role [7,8].
The best characterized HP virulence marker is the cytotoxin-
associated gene pathogenicity island (cagPAI), a 40 kb region of
chromosomal DNA encoding approximately 31 genes that forms a
type IV secretion system (T4SS) to translocate bacterial products
into the host cell. cagA resides within cagPAI and is responsible for
most of the HP-associated malignant phenotypes: it triggers IL-8
secretion priming an inflammatory response, promotes cell
proliferation, scattering and migration either through phosphor-
ylation-dependent and independent mechanisms [9,10]. The
cagPAI is present in approximately 95% of East Asian isolates
and it is less frequent in isolates from low risk Western countries
[11,12,13].
Many of the cagA functions reside within a C-terminal
tandemly arrayed repetitive motif containing the aminoacids
Glu-Pro-Ile-Tyr-Ala (EPIYA motifs A, B, C and D). Strains
harboring multiple copies of western type EPIYA-C or eastern
type EPIYA-D are suggested to be more associated with gastric
cancer and with an increased cagA in vitro activity [14], although
this is controversial [15]. To date, despite the known variability in
the N-terminal cagA gene and other cagPAI island genes, there has
been very limited information concerning clinical relevance of
genetic variants outside the EPIYAs. Thus, in this paper we seek to
identify variants in the cagPAI genes cagC (HP0546), cagE
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Gamma (HP0523) genes, which have been designated as important
functional components of model bacterial T4SS, and are known to
be crucial for cagPAI translocation function or present extracel-
lularly, suggesting a possible interactions with host cells; and in
cagA, whose EPIYA region has been consistently shown to
correlate with clinical outcome (gastric cancer) [16].
cagA status alone is not sufficient to predict clinical outcomes.
Moreover there are indications that HP eradication reduces gastric
cancer incidence only in individuals without precancerous lesions.
The results of this study may provide valuable information to
target antibiotic treatment to high risk individuals, if effects of
these variants are confirmed in further investigations.
Materials and Methods
Ethics Statement
All participants signed an informed written consent. The study
was approved by the ethical review boards of the institutions
responsible for subject recruitment in each of the recruitment
centres.
For Mexican samples, the study was approved by ethical
committees of the Instituto Mexicano del Seguro Social (IMSS)
and General Hospital of the Secretaria de Salud (SS), Mexico City,
Mexico.
For Venezuelan samples, ethical clearance for the study was
obtained from the International Agency for Research on Cancer
(IARC) Ethical Committee in Lyon, France, and the Cancer
Control Center in San Cristobal, Venezuela.
Study population
Venezuela. We used 11 DNA samples from gastric biopsies
from subjects affected with chronic gastritis without atrophy
recruited in a chemoprevention trial in Venezuela [17,18]. The
study subjects (age 35-69) in this trial were recruited from
participants in the Gastric Cancer Control Program of Tachira
State, which was based on a gastric double contrast X-ray followed
by a gastroscopic examination. Subjects with any cancer including
gastric cancer, or with any other serious illnesses such as heart,
lung, kidney or liver failure and pregnant women were not eligible.
Seven gastric biopsies were taken from predefined sites, five for
histological evaluation and two were frozen for H pylori DNA
isolation or culture. Expert pathologists in neoplastic lesions of the
stomach read histological slides.
Mexico. 84 samples were from patients attending the
Gastroenterology Unit of the Me ´xico General Hospital
(Secretarı ´a de Salud) and the Oncology Hospital (Instituto
Mexicano del Seguro Social), both hospitals in Mexico City.
Thirty-five patients were affected with chronic gastritis and 49
with gastric cancer. Patients were older than 30 years, consulted
because of gastroduodenal symptoms (General Hospital) or
because of a probable gastric cancer (Oncology Hospital), and
were programmed for endoscopy and biopsy for diagnostic
purposes. Subjects who had previously received cancer
treatment, were on antibiotics, anti-HP therapy or nonsteroidal
anti-inflammatory drugs two weeks prior to the study, or had other
severe chronic diseases were excluded. Gastric biopsy specimens
were placed in sterile 0.9% saline solution, homogenized, and
inoculated onto blood agar base (BBL, MD) plates supplemented
with 5% sheep blood for HP culture. The plates were incubated at
37uC in a 9% CO2 atmosphere for up to 5 days. HP was identified
by colony and microscopic morphology and by positive oxidase,
catalase, and urease tests. From each primary growth, 7 to 10
single colonies each were isolated from the antrum and corpus and
propagated on blood agar medium. For this study, we analyzed 43
samples from cultured strains and 41 directly from frozen biopsies.
The principal characteristics of the population are described in
table 1.
Table 1. Characteristics of the populations and numbers of Mexican and Venezuelan samples for individual genes and regions of
cagA analyzed.
Mexican Venezuelan Total
Number of samples 84 11 95
Diagnosis Cancer cases 49 0 49
Gastritis cases 35 11 46
Gender Female 48 4 52
Male 36 7 43
Median age Cancer cases 58 (49–69) - 58 (49–69)
(25%–75%) Gastritis cases 44 (39.5–56.5) 54 (42.5–58.5) 46.5 (40–57.75)
Samples analyzed per gene
CagA N terminal 76 9 85
CagA middle region 34 9 43
CagA EPIYA motif region 60 10 70?
CagC 35 9 44
CagE 38 9 47
CagL 33 0 33
CagT 34 4 38
CagV 18 9 27
Cag Gamma 28 0 28
doi:10.1371/journal.pone.0029605.t001
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For Venezuelan and Mexican biopsy samples the DNA was
extracted from frozen tissues using QIAamp DNA Micro Kit
(Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. For cultured strains DNA was purified using the
guanidine thiocyanate-EDTA-Sarkosyl (GES) method [19].
Primer design
We used alignments of HP sequences from public databases to
identify sequences suitable for design of PCR primers. We limited
our database searches to Western strains of HP, which are more
likely to be similar to the strains found in our study samples. We
designed tiled amplicons ranging in size from 312 to 876 bp. The
average size of sequence reads with 454 sequencing technology is
450 bp, therefore forward reads and reverse reads overlap at least
partially, thereby improving the reliability of the output. Five of
the cagA amplimers used have been previously published [20,21].
All primers used for cagA, cagC, cagE, cagL, cagV, cagT and cag gamma
were first tested in PCR reactions on a small number of study
samples (n=16) and the amplified regions were sequenced with
Sanger technology on the same samples to confirm the specificity
of the amplification (see supplementary table S1 for primer
sequences and PCR amplification conditions).
Furthermore, we used, as reference, three strains 26695
(NC_000195), J99 (NC_000921) and G27 (NC_0011333) whose
genomes have been completely sequenced [22,23,24].
454 sequencing
Once PCR conditions were optimized, we resynthesized the same
primers used for PCR with multiplex tags (used to identify sequences
from each specific sample) and adaptors, and amplified the target
regions using DNAs from samples. A second PCR was performed,
using the tagged primers, in order to increase the amount of
material. All PCR amplimers were then purified, quantified
spectrophotometrically, and pooled in equimolar amounts.
Librarygenerationfor454FLXsequencing wascarried outusing
the manufacturer’s standard protocols (454 Life Sciences Corpora-
tion, Branford, CT, USA). In short, the manufacturer’s adaptors
required forprocessing and sequencingwereadded to the terminiof
each pool of tagged PCR products by ligation. Single molecules of
the PCR products carrying the correct adaptors were hybridized to
individual beads, clonally amplified in a subsequent emulsion PCR
and each pool loaded onto a 1/16 of a picotiterplate for sequencing
using the 454 GS FLX Titanium technology. After processing and
base calling using the manufacturer’s proprietary software (454 Life
Sciences Corporation, Branford, CT, USA, Software version 2.0.00
October 2008) the resulting reads were sorted according to the pre-
incorporated six base tags. Genomic sequence analysis by 454
technology was performed for these HP isolates with .200-fold
average coverage (minimum 59x, maximum 580x). The resulting
contigs were assembled using the gene sequence of HP strain 26695
[23] as a scaffold. We have not observed substantial differences in
quality of the output between DNA from cultured strain and DNA
from biopsies. In order to assess quality control of the data we
compared 454 sequencing data of the reference strain 26695 and
the published sequence in NCBI database (NC_000915); concor-
dance was over .99%. We also sequenced 9 Venezuelan samples
with the traditional Sanger sequencing method, observing a
concordance .99% between methods.
Sanger sequencing
The cagA N-terminal (630bp), C-terminal (position 2670-3100)
and EPIYA motifs region as well as cagL gene were sequenced by
the Sanger method. The sequencing reactions were performed
using BigDyeR Terminator Cycle Kit (Applied Biosystems, Foster
City, CA, USA) under thermal conditions as follow: 96uC for
2 min, and then 27 cycles at 96uC for 30 s, 54uC for 10 s and
60uC for 4 min. The reaction products were precipitated with 2-
propanol, washed with 75% ethanol, diluted in 25 ml water and
loaded onto an ABI prism 3100 Genetic analyzer (Applied
Biosystems). Primary sequencing data were analyzed using a
sequencing analysis program (Applied Biosystems).
Bioinformatic and statistical methods
Raw sequences were automatically analyzed with the 454
software, and quality scores were assigned. The resulting
sequencing output, from both 454 in sff format and Sanger in
abi format, was analyzed with multiple sequence alignment
software (e.g. the Geneious software platform: http://www.
geneious.com/), which assembled all reads belonging to the same
sample, then sequences of all the samples were aligned to a
reference sequence and single nucleotide polymorphisms as well as
small insertions and deletions were identified. To avoid potential
artifacts from sequencing and to limit variants with clinically and
statistically meaningful frequencies, we selected variants with
unambiguous calls observed in at least 10% for synonymous
(N=175) and 20% for nonsynonymous (N=206) variants of the
originally tested samples and reference strains (Total 381).
SAS version 9.2 was used to estimate logit odds ratios (OR) and
95% confidence interval (CI) for gastric cancer associated with
each variant as well as to calculate p-values for differences in
variant frequencies between gastric cancer and gastritis by the
Fisher’s exact test (2-sided). Bonferroni correction was applied to
compute p-values adjusted for multiple comparisons by dividing
raw p-values with 381.
Genetic variability in seven HP cagPAI genes
A summary of the genetic variability detected in the seven genes
is reported in table 2. As expected, we observed a high degree of
variability (computed as the number of sites showing a variant out
of the total of sites in a gene), both at the DNA and amino acid
level. The nucleotide variability ranged from 8.03% in cagV to
23.92% in cagC, while the amino acid variability interestingly
ranged from 5.69% in cagT, showing the smallest degree of
variation, to 31.01% in cagA.
We compared the frequencies of the 381 selected genetic
variants between gastric cancer and chronic gastritis cases. We
then determined non-synonymous (table 3) and synonymous
(table 4) variants that showed appreciable differences between
gastritis and cancer cases, meeting one of the following criteria, (1)
absolute variant frequency differed at least 25% between gastritis
and cancer groups; (2) variant frequency in gastric cancer at least
twice as high as in gastritis and (3) variant frequency in gastritis at
least twice as high as in gastric cancer. Twenty-five SNPs (11 non-
synonymous and 14 synonymous) reached statistically significant
differences (p,0.05, figure 1), located in cagA, cagE, caggamma and
cagL, whereas none were located in cagC, cagT or cagV. We then
applied a study-wise threshold of p=1.31610
24 (0.05/381)
adjusted for multiple comparisons, and only two SNPs, in position
1039 and 1041 in cagE, showed a p-value lower than this
threshold. A SNP in the cagE gene (position 1905) shows a p value
of 2.55610
24 very close to the study-wise statistical significance.
cagA polymorphisms and EPIYA types
The C-terminal region (positions 2670 to 3100) was highly
variable in the clinical isolates according to the pattern of the
EPIYA motifs (figure 2). We observed 524 polymorphic sites of
Polymorphisms in Hp cagPAI and Gastric Cancer Risk
PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e29605which we analyzed 148 selected with the criteria previously
described (the complete catalog of cagA SNPs is shown in
supplementary file S1). Interestingly, two SNPs show a different
recurrence between gastritis and cancer cases with p,0.05, even if
they were not considered statistical significant due to the large
number of tests; one is a non-synonymous SNPs (A2033G
determine an amino acid change T/A, see table 3) and one
synonymous SNPs (A2547G, see table 4).
The analysis of the EPIYA region confirmed that all sequences
were of the Western type cagA, i.e., ABC (82%), ABCC (13%),
ABABC (3%), AABCC (1%) and ABCCC (1%). We did not
observe a different distribution of these cagA types between the
cancer and gastritis cases (p=0.2342), detailed results are shown in
table 5 and figure 2. We observed 3 variants of the EPIYA motif:
one gastritis sample had EPIYV in an A motif, 50% of B motifs
showed the EPIYT variant (no statistical different distribution in
cancer and gastritis case) and one C motif of a cancer case showed
a EPLYA variant.
Results in the other cagPAI genes
Genetic variability of cagC cagE, cagT, cagV and cag Gamma was
assessed by 454 sequencing and of cagL by Sanger sequencing. The
complete catalog of polymorphisms observed in these seven genes
is shown in supplementary file S1.
In the cagC gene we detected 83 SNPs, 25 of which were selected
as described above. None of these SNPs showed a differential
distribution between gastritis and cancer cases.
In the cagE gene we have catalogued 308 polymorphic sites, 97
of these polymorphisms were analyzed. C1039T and T1041G
showed a statistically significant different recurrence between
gastritis and cancer cases with p=9.97610
26. Furthermore
another SNP T1905C showed a different recurrence with a p
value of 2.55610
24, which is very close to the study-wise
threshold. Nine other SNPs show a different recurrence between
gastritis and cancer cases with p,0.05, six synonymous polymor-
phisms (T1032C, C1038T, T2092C, A2097G, G2121A and
A2286G) and 3 non-synonymous variants: A76C (aminoacidic
change from lysine to glutamine), T1853C (aminoacidic change
from valine to alanine) and A2032G (aminoacidic change from
asparagine to aspartic acid).
The C1039T variant, when analyzed as single change, predicts
an amino acid change of lysine to phenilalanine (codon change of
CTT to TTT), whereas the SNP T1041G lies at the third position
of the same codon and if analyzed as single change it predicted a
synonymous variant (codon change CTT to CTG). However, in
all the samples that we have analyzed the two variant alleles were
observed together, therefore we observed only two variant codons
(CTT and TTG) which encode for the same amino acid, lysine.
The T1905C polymorphism is a synonymous variant at the third
position of the GTT codon (variant codon GTC), which codes for
Valine.
In the cagL gene we observed 74 polymorphisms and 24 of
which were analyzed, 4 showed a differential distribution between
cases of cancer and gastritis (P,0.05). Two of them were non-
synonymous: G166A (aminoacidic change of alanine to threonine)
and A172G (aminoacidic change of asparagine to aspartic acid)
and two synonymous: (A228G and C516T).
In the cagT gene we analyzed 23 of the 81 polymorphisms
observed, while in the cagV gene we analyzed 11 of the 61
polymorphisms, and in both genes none of the polymorphism
showed a differential distribution between gastritis and cancer
cases.
In the cag Gamma gene we observed 111 polymorphisms, 53 of
which were further analyzed and 4 synonymous (A195TorC,
T207A, C264T and A468G) and five non-synonymous (A38G,
C47G, A200/201T, A367C and G457A) showed a p,0.05 for the
differential distribution between gastritis and cancer cases
(figure 1).
Discussion
Since its discovery in 1996 [25], the cagPAI, which harbors the
virulence genes of HP, has probably been the most intensively
studied part of the HP genome. The type IV secretion system
encodes proteins, which form a needle-like structure connecting
HP to the cytoplasm of the epithelial gastric cell to inject the
oncogenic CagA protein and peptidoglycans. Components of this
structure include a) pilus components, CagC (homologue of the
Agrobacterium tumefaciens VirB2) forming the main extracellular
structure, to which the tip CagL is attached to interact with b-1
integrin; b) core complex proteins, CagW (VirB6), CagT (VirB7),
CagV (VirB8), CagX (VirB9) and CagY (VirB10) which form the
inner core of the pilus; c) energetic factors Cagb (VirD4), Caga
(VirB11) and CagE (VirB3/VirB4), ATPases supplying energy for
the system to work [26]. In this study we have sequenced cagC
(HP0546), cagL (HP0539) from the pilus, cagV (HP0530), cagT
(HP0533), and cag Gamma (HP0523) from the core complex, and
cagE (HP0544) from the energy supply enzymes from HP strains
isolated from gastritis and gastric cancer patients. These genes
were chosen because their products are known to be essential for
Table 2. Summary of genetic variability in seven genes in HP cagPAI.
Gene
Number of
nucleotides
Nucleotide
differences
a
Nucleotide
differences
(%)
Non-
synonymous
variants
Non-
synonymous
variants (%)
Number of
amino acids
Amino acid
differences
a
Amino acid
differences (%)
cagA 2670* 524 19.63% 333 63.55% 890* 276 31.01%
cagC 347 83 23.92% 32 38.55% 115 27 23.48%
cagE 2955 308 10.42% 68 22.08% 984 58 5.89%
cagL 714 74 10.36% 31 41.89% 237 29 12.24%
cagT 842 81 9.62% 18 22.22% 281 16 5.69%
cagV 759 61 8.03% 18 24.59% 253 15 5.93%
cagGamma 509 111 21.81% 40 36.04% 169 33 19.53%
aComputed as the number of sites showing a variant out of the total of sites (nucleotides or aminoacids) in a gene.
*single nucleotide polymorphisms in the EPIYA motif region are excluded.
doi:10.1371/journal.pone.0029605.t002
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(CagA, CagL, CagC), suggesting possible interactions with the host
cell [27].
We found the smallest variation, both at nucleotide and
aminoacid level, in the inner core T4SS components (CagT, CagV,
and CagE; 5.7%, 5.9% and 5.9% aminoacid variation, respective-
ly), and the largest variation in the exposed components: integrin
binding protein CagL, extracellular pilus main component CagC
and secreted protein CagA (12.2%, 23.5% and 31%, aminoacid
variation, respectively). These results support that genetic variation
in cagPAI components is mainly influenced by their localization in
the T4SS, with higher variation in proteins exposed in the bacterial
surface, perhaps as a response to immunological pressure.
Interestingly, Cag Gamma was an exception (19.5% aminoacid
variation), this protein has been proposed to reside within the HP
periplasm where it acts as a peptidoglycan hydrolase, piercing the
HP outer membrane and thus helping to expose the T4SS pilus to
the external medium [28]. It is possible that Cag Gamma fulfills this
function also as a structural component of the exposed pilus, where
it could also act over the host cell membrane.
Studies from Africa [21],Italy [14], USA[8]and Brazil[29] have
suggested an association between increased number of EPIYA C
motifsand HPassociated diseases. Furthermore, Sicinschiet al. [30]
observed an association between increased EPIYA C segments and
the presence of gastric precancerous lesions. In contrast, studies in
Colombia [8,31], Mexico (J. Torres, personal communication), and
Korea [32] have not found such an association. In our study, over
80% of all samples from Mexico and Venezuela were of the type
ABC, and no association was evident between gastric cancer
progression and higher number of EPIYA C motifs. Moreover,
Table 3. Non-synonymous variants with frequency greater than 10% in all samples and more of 25% difference in the prevalence
between cancer and gastritis or the prevalence in one group at least twice as high as in the other group.
Genes
Position
in 26695
a
Position
in contig
Nucleotide
Change
Amino acid
change
Gastric
cancer
cases/Cases
of gastritis
Gastric
cancer
cases %
Cases of
gastritis % OR (95% CI)
b
Fisher P-
value
cagA 193 193 GRAG RR 44/40 13.6% 5.0% 3.00 (0.57–15.81) 0.269
cagA 334 334 ARGK RE 45/39 15.6% 7.7% 2.21 (0.53–9.21) 0.327
cagA 344 344 ARGQ RR 45/39 15.6% 7.7% 2.21 (0.53–9.21) 0.327
cagA 623 623 CRGT RS 37/40 20.0% 8.1% 2.83 (0.69–11.63) 0.196
cagA 1696/1697 1696/1697 ARG/CRTT RI/V 16/25 50.0% 80.0% 0.25 (0.06–1.00) 0.084
cagA 1814 1819 GRAS RN 16/25 56.3% 84.0% 0.24 (0.06–1.05) 0.074
cagA 2033 2038 ARGT RA 16/25 12.5% 48.0% 0.15 (0.36–0.88) 0.041
cagA 2341 2347 ARTI RF 16/25 25.0% 12.0% 2.44 (0.47–12.78) 0.401
cagC 95 95 GRAS RN 15/28 26.7% 10.7% 3.03 (0.58–15.88) 0.215
cagC 100 100 GRAA RT 15/28 6.7% 17.9% 0.33 (0.03–3.11) 0.403
cagC 331 331 ARGS RG 15/28 40.0% 14.3% 4.00 (0.91–17.55) 0.073
cagE 43 43 GRAV RI 17/28 35.3% 64.3% 0.30 (0.09–1.07) 0.073
cagE 115 115 GRAV RI 17/28 29.4% 14.3% 2.50 (0.57–11.06) 0.265
cagE 1039 1042 CRTL RF 17/28 82.4% 10.7% 39.89 (6.90–219.11) 2.07610
26
cagE 1661 1664 ARGN RS 17/28 5.9% 17.9% 0.29 (0.03–2.70) 0.385
cagE 1853 1856 TRCV RA 17/28 23.5% 64.3% 0.17 (0.04–0.67) 0.013
cagE 2032 2035 ARGN RD 17/28 29.4% 67.9% 0.20 (0.05–0.73) 0.016
cagE 2509 2512 GRAG RS 17/28 29.4% 14.3% 2.50 (0.57–11.05) 0.265
cagL 95 95 GRAS RN 7/16 57.1% 18.8% 5.78 (0.82–40.76) 0.137
cagL 166 166 GRAA RT 7/16 57.1% 6.3% 20.00 (1.63–247.98) 0.017
cagL 172 172 ARGN RD 7/16 28.6% 81.3% 0.09 (0.01–0.73) 0.026
cagL 180 180 GRAM RI 7/16 57.1% 25.0% 4.00 (0.61–26.12) 0.182
cagL 524 529 CRTT RI 10/17 10.0% 23.5% 0.36 (0.03–3.79) 0.621
cagGamma 12 38 ARGN RS 10/17 40.0% 5.9% 10.67 (0.98–115.68) 0.047
cagGamma 38 47 CRGA RG 10/17 40.0% 5.9% 10.67 (0.98–115.68) 0.047
cagGamma 47 67 ARGT RA 10/17 20.0% 5.9% 4.00 (0.31–51.03) 0.535
cagGamma 200/201 200/201 ARTK RI 10/17 40.0% 88.2% 0.09 (0.01–0.62) 0.025
cagGamma 205/206 205/206 CRA/TRCL RP/T 10/17 20.0% 52.9% 0.22 (0.03–1.37) 0.124
cagGamma 314 314 GRAG RD 10/17 10.0% 41.2% 0.16 (0.02–1.55) 0.190
cagGamma 367 367 ARCK RQ 10/17 40.0% 5.9% 10.67 (0.98–115.68) 0.047
cagGamma 457 457 GRAA RT 9/16 22.2% 68.8% 0.13 (0.02–0.86) 0.041
aReference strain 26695 (reference in GenBank: NC_000915).
bOR= odds ratio; CI=confidence interval.
doi:10.1371/journal.pone.0029605.t003
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EPIYA B motif for activity on epithelial cells, we observed four non
synonymous variations in this motif, but these polymorphisms did
not show an association with gastric cancer.
Recent studies have reported important pro-inflammatory and
pro-oncogenic activities of CagA that are independent of the
EPIYA motifs and which might be as important for disease [30];
these findings could explain the lack of association of C motifs with
cancer reported here and in previous studies. The C terminal of
CagA protein also contains the C-MET motif which has been
proposed to have several functions: mediate CagA multimerization
and membrane targeting [33,34], interact with the kinase Par1b/
MARK2 [35], and all these activities are CagA-phosphorylation
independent [36]. However, in our study we did not find
significant differences between gastritis and gastric cancer, either
in sequence or in the number of multimerization motifs.
The C-terminal and N-terminal domains of CagA are both
required to exploit the full activity of the protein, although they
have distinct functions. Recently it has been shown that the N
terminus of CagA interacts with the tumor suppressor apoptosis-
stimulating protein of p53 (ASPP2) [37].
The presence of all these interactions between CagA and
bacterial and human proteins suggest that it could be very difficult
for the bacterium to maintain the full range of biological activity in
the presence of high level of mutations, most of which presumably
lead to loss or attenuation of function.
Table 4. Synonymous variants with a frequency greater than 20% in all samples and more of 25% difference in the prevalence
between cancer and gastritis or the prevalence in one group at least twice as high as in the other group.
Genes
Position
in 26695
a
Position
in contig
Nucleotide
change
Gastric cancer
cases/Cases
of gastritis
Gastric
cancer
cases %
Cases of
gastritis
% OR (95% CI)
b
Fisher
P-value
cagA 858 861 TRC 16/25 12.5% 40.0% 0.21 (0.04–1.15) 0.084
cagA 870 873 TRC 16/25 62.5% 36.0% 2.96 (0.81–10.88) 0.120
cagA 1743 1746 CRT 16/25 50.0% 76.0% 0.32 (0.08–1.21) 0.105
cagA 2547 2553 ARG 16/25 31.3% 68.0% 0.21 (0.06–0.83) 0.029
cagC 252 252 CRT 15/28 60.0% 32.1% 3.17 (0.86–11.65) 0.109
cagC 288 288 TRC 15/28 6.7% 32.1% 0.15 (0.02–1.33) 0.127
cagE 69 69 CRG 17/28 52.9% 78.6% 0.31 (0.08–1.14) 0.101
cagE 72 72 ARG 17/28 52.9% 78.6% 0.31 (0.08–1.14) 0.101
cagE 462 462 GRA 17/28 41.2% 67.9% 0.33 (0.10–1.16) 0.121
cagE 1011 1011 CRT 17/28 70.6% 42.9% 3.20 (0.89–11.56) 0.123
cagE 1032 1035 TRC 17/28 11.8% 42.9% 0.18 (0.03–0.93) 0.046
cagE 1038 1041 CRT 17/28 94.1% 64.3% 8.89 (1.02–77.32) 0.033
cagE 1041 1044 TRG 17/28 82.4% 10.7% 38.89 (6.90–219.11) 2.067610
26
cagE 1164 1167 TRC 17/28 11.8% 25.0% 0.40 (0.07–2.20) 0.447
cagE 1905 1908 TRC 17/28 29.4% 85.7% 0.07 (0.02–0.31) 2.55610
24
cagE 2058 2061 ARG 17/28 35.3% 64.3% 0.30 (0.09–1.07) 0.073
cagE 2092 2095 TRC 17/28 35.3% 71.4% 0.22 (0.06–0.79) 0.029
cagE 2097 2100 ARG 17/28 35.3% 71.4% 0.22 (0.06–0.79) 0.029
cagE 2121 2124 GRA 17/28 47.1% 89.3% 0.11 (0.02–0.49) 0.004
cagE 2286 2289 ARG 17/28 52.9% 89.3% 0.14 (0.03–0.62) 0.011
cagL 228 228 ARG 7/16 71.4% 12.5% 17.50 (1.82–159.53) 0.011
cagL 375 379 GRA 7/16 27.3% 57.9% 0.27 (0.05–1.36) 0.142
cagL 477 482 TRC 10/17 10.0% 23.5% 0.36 (0.03–3.79) 0.621
cagL 516 521 CRT 10/17 90.0% 47.1% 10.13 (1.05–98.49) 0.042
cagT 336 339 TRC 14/23 21.4% 47.8% 0.30 (0.07–1.36) 0.166
cagT 339 342 ARG 14/23 21.4% 43.5% 0.35 (0.08–1.62) 0.288
cagV 243 243 CRA 8/18 62.5% 22.2% 5.83 (0.95–35.72) 0.078
cagV 306 306 ARC 8/18 87.5% 55.6% 5.60 (0.57–55.43) 0.190
cagGamma 150 150 CRT 10/17 60.0% 88.2% 0.20 (0.03–1.40) 0.154
cagGamma 195 195 ARC/T 10/17 40.0% 88.2% 0.09 (0.01–0.62) 0.025
cagGamma 207 207 TRA 10/17 40.0% 88.2% 0.09 (0.01–0.62) 0.025
cagGamma 264 264 CRT 10/17 40.0% 100.0% 0.02 (0.00–0.42) 0.001
cagGamma 468 468 ARG 9/16 88.9% 43.8% 10.29 (1.03–102.75) 0.041
aReference strain 26695 (reference in GenBank: NC_000915).
bOR= odds ratio; CI=confidence interval.
doi:10.1371/journal.pone.0029605.t004
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cagA status alone is not sufficient to predict clinical outcomes in
high risk populations where the majority of HP are cagA-positive
strains. In this context, identification of new HP molecular
virulence markers to predict gastric cancer risk will be very
important. Recent progress in genotyping methodology enables us
to use DNA from gastric biopsies to study HP sequence
microvariabilities, which have been almost exclusively studied in
cultured strains. Genotyping of a higher number of gastric samples
allows us to expand cagPAI genetic variant detection to other
potentially important T4SS genes. This is relevant since earlier
studies have focused mainly on cagA and the utility of other cagPAI
genes as markers for disease risk is scarcely studied. Few studies
have looked for the association of presence of cagPAI genes and
disease, and none have studied polymorphisms in cagPAI genes,
other than cagA.
cagE is a unique gene that encodes two T4SS components,
VirB3 (N-terminal) and B4 (C-terminal) as a fusion protein[38],
and B4 is the largest ATPase among several T4SS components. It
generates energy for the secretion process, thus is required for
substrate translocation [39] and interacts with many other T4SS
proteins including VirB2 [40]. Despite its relatively inner
localization, its pivotal role in IL-8 induction has been well
documented [41,42,43]. Interestingly, we observed a strong
association between two SNPs (C1039T and T1041G) of the cagE
and gastric cancer, a finding not reported previously. These SNPs
are at the position one and three of the same codon and we always
observed these two variant codons (CTT and TTG) which codify
for the same amino acid, lysine. This variant codon is located in
the homology domain with VirB3 of Agrobacterium. The second
strongest association was detected in another synonymous SNP in
position 1905 and in this case the two possible codons were GTT
and GTC, which code for valine. It has been known for a long
time that alternative synonymous codons are not used with equal
frequencies and patterns of codon usage vary among species [44].
Codon usage is more biased in genes expressed at higher levels
[45,46]. The use of optimal codons allows for more efficient use of
ribosomes and leads to faster growth rate [47]. Although the
genome of HP has been reported to contain no codon bias for
highly expressed genes [48], Kloster and Tang [49] identified a
bias in the expression level of genes where TTG codon is preferred
over the CTT codon, as well as of the GTC codon over the GTT.
Therefore, based on these data we could speculate that difference
in codon usage may have an impact on the level of expression of a
gene with a strong functional relevance for the T4SS secretion
system such as cagE.
CagL is a specialized pilus protein that binds to and activates
integrin a5b1 receptor on gastric epithelial cells primarily through
its arginine-glycine-aspartate (RGD) motif, guiding proper posi-
tioning of the T4SS and facilitating translocation of cagA [9,50].
CagL also activates the host cell kinases focal adhesion kinase
(FAK) and Src to ensure CagA phosphorylation at the site of
injection, whereas b1 integrin is required for CagA-induced host
cell motility and elongation [51]. CagL may also be responsible for
HP-induced hypochlorhydria through activation of a disintegrin
and metalloprotease 17 and of NFkB [52]. Of the two cagL SNPs
we found associated with gastric cancer, the A172G SNP (N58D)
is in the same position in which Yeh et al [53] have demonstrated
Figure 1. Summary of thirty-one SNPs (10 non-synonymous and 21 synonymous) showing statistically significant differences
(P,0.05) between gastritis and gastric cancer cases. The color coding is as follows: SNPs in green are synonymous variants, SNPs in blue are
not synonymous variants and SNPs in red are those with strong statistical significance (study-wise threshold of P=1.31610
24).
doi:10.1371/journal.pone.0029605.g001
Figure 2. Scheme of the alignment of the EPIYA motifs with number of observations in Mexican and Venezuelan populations.
doi:10.1371/journal.pone.0029605.g002
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and glutamic acid in position 59 (Y58E59) compared with the
combination aspartic acid (D58) and Lysine (K59), induces more
efficiently a corpus shift of gastric integrin a5b1 which has been
related with gastric carcinogenesis. We did not observe the
tyrosine (Y) amino acid in position 58 in any sample, although we
found that carriers of aspartic acid (D) at this position are at lower
risk of gastric cancer in comparison with the asparagine (N)
carriers. Furthermore, we observed the polymorphism in amino
acid 59 at lower frequency and without any difference between
cancer and gastritis samples.
In previous studies [54] sequence analysis of cagGamma gene
showed that it harbors a typical SLT catalytic domain between
residues 33 and 165, whose ‘‘ES’’ and ‘‘AVGAY’’ motifs were
highly conserved among the ortholog enzymes. We observed five
nonsynonymous variants with a different distribution in cancer
and gastritis cases. Three of those map in the catalytic domain,
nevertheless none of them is located in the most conserved parts of
the domain.
Although this study has limitations in sample size, it is the largest
up to now in terms of the number of cagPAI genes studied for a
deep sequence analyses. A few samples were lost because of failure
in PCR amplification, which may be due to microvariabilities of
HP sequence. Loss due to poor quality score from 454 sequencing
are relatively limited and derive from low efficiency of original
PCR, which did not allow a equimolar pooling. We limited
statistical analysis to variants with very high frequencies to avoid
potential artifacts from high throughput sequencing; consequently,
it is possible that rare variants with significant effect on T4SS
functions are not represented in this study. Still, it is unlikely that
such variants account for a sizable fraction of patients who develop
HP associated gastric cancer.
Our study was limited to Venezuelan and Mexican populations
and the results cannot necessarily be extrapolated to other
populations. Particularly we did not observe any Eastern strains
and we cannot analyze the impact of these polymorphisms on such
different genetic background. In fact, analysis of EPIYA motifs
between Venezuelan and Mexican strains showed a highly similar
distributions in the two populations, which share similar genetic
background. Furthermore the exclusion of Venezuelan samples
did not change the results on cagE position 1039/1041
polymorphisms, which remained highly statistically significant
(Fisher p-value = 5.04610
25). In addition, because the numbers
of gastric cancer cases assessed for individual cag genes were very
limited (generally ,20), it was not statistically appropriate to
include extra covariates such as age. Age is an important
determinant of gastric cancer risk and may exert the cohort effect
on the type of strains acquired. However, when we examined the
effects of age on the prevalence of specific cag A/E/L and gamma
SNPs associated with gastric cancer risk, the association was not
statistically significant with p-values ranging from 0.130-0.930.
Thus, we believe the effect of confounding from age is very small if
any.
It is also possible that strains from cancer cases may simply
represent the ones that can survive in a cancer environment. As
gastric adenocarcinoma is known to arise from several stages of
premalignant lesions, i.e., chronic gastritis, atrophic gastritis,
intestinal metaplasia (IM) and dysplasia, induced by HP infection
[2,55], these associations need to be confirmed using samples from
various stages of premalignant lesions in future. Furthermore,
functional tests are warranted to clarify the role of these variants in
the pathogenicity and address future studies towards more
targeted preventive interventions. We are planning to test strains
with variants in cagE and cagL in cultured epithelial cells to
elucidate if translocation and morphology effects are altered, and
in a mouse model to study their ability to induce gastric tumors.
Although cagA is the best established HP virulence marker, cagA
status alone is not sufficient to predict clinical outcomes in high
risk populations where the majority of HP are cagA-positive strains.
In this study we show that polymorphisms in genes coding for
energy-supply protein CagE and for the b-1 integrin recognizing
CagL may also affect virulence, most probably because they are
necessary for a functional secretory system. We also document that
genetic variation is higher for genes encoding proteins exposed to
the host milieu, probably because of a positive selection exerted by
the inflammatory and immune response of the host.
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